



FOR INFORMATION

NicOx's June 16 Shareholder Meetings

June 4, 2010. Sophia Antipolis, France. www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) wishes to remind its shareholders that its shareholder meetings are convened on second call on Wednesday June 16, 2010 at 10:00 am CET at the Company's headquarters. NicOx wishes to ask its shareholders to support the Company by voting at the shareholder meetings.

To participate in NicOx's shareholder meetings, shareholders are kindly requested to send to NicOx a share certificate (*'attestation de participation'*) dated June 11 at the latest to be issued by the bank or financial intermediary holding the shares (in bearer form). Shareholders who cannot attend the meeting in person are further requested to send to the Company's headquarters, before June 13, a signed proxy form. This proxy form can be used to vote by correspondence or to give proxy to the Chairman, to another shareholder or to the shareholder's spouse.

The proxy form, the agenda of the meetings, the resolutions submitted to the vote and practical advice on how to vote can be obtained on NicOx's website (www.nicox.com) or upon written or telephone request.

Further, the documents mentioned in articles R.225-81 and R.225-83 of the French *Code de commerce* can also be obtained by written or telephone request.

Risks factors which are likely to have a material effect on NicOx's business are presented in the 4th chapter of the « *Document de référence, rapport financier annuel et rapport de gestion 2009* » filed with the French *Autorité des Marchés Financiers* (AMF) on March 5, 2010 and available on NicOx's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

The Company notably draws the investors' attention to the following risk factors:

- *Risques liés à la dépendance de la Société à l'égard du naproxinod* (Risks related to the Company's dependence on the success of its lead product naproxinod)
 - *Risques commerciaux et développements cliniques* (Clinical developments and commercial risk)
 - *Risques liés aux contraintes réglementaires et à la lenteur des procédures d'approbation* (Risks linked to regulatory constraints and slow approval procedures)
 - *Manque de capacités dans les domaines de la vente et du marketing* (Lack of sales and marketing capabilities)
 - *Incertitude relative aux prix des médicaments et aux régimes de remboursement, ainsi qu'en matière de réforme des régimes d'assurance maladie* (Uncertainty on drug pricing and reimbursement policies and on the reforms of the health insurance systems)
-

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NME) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

NicOx's lead investigational compound is naproxinod, an NME and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate developed for the relief of the signs and symptoms of osteoarthritis (OA), which is currently under review by regulatory authorities, following the submission and filing of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). The FDA has set an action date of July 24, 2010, under the Prescription Drug User Fee Act (PDUFA).

In addition to naproxinod, NicOx's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, including Merck & Co., Inc. and Bausch + Lomb, for the treatment of hypertension, cardiometabolic diseases, widespread eye diseases and dermatological diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Référence filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on NicOx S.A.'s website (<http://www.nicox.com>).

CONTACTS: www.nicox.com

NicOx: Gavin Spencer Vice President Business Development
Tel +33 (0)4 97 24 53 00 • communications@nicox.com

Media Relations Financial Dynamics

Europe Guillaume Granier (France) • Tel: +33 (0)1 47 03 68 10 • guillaume.granier@fd.com
Stéphanie Bia (France) • Tel: +33 (0)1 47 03 68 10 • stephanie.bia@fd.com
Jonathan Birt (UK) • Tel +44 (0)20 7269 7205 • jonathan.birt@fd.com

United States Robert Stanislaro • Tel +1 212 850 5657 • robert.stanislaro@fd.com
Irma Gomez-Dib • Tel +1 212 850 5761 • irma.gomez-dib@fd.com